Skip to content
MARKETS / NASDAQ / HYPD
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Hyperion Defi, Inc. HYPD

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$813,455
▲ 1318.8% YoY
$-45.3M
In brief

What this company does

Hyperion DeFi is working to provide its shareholders with simplified exposure to the Hyperliquid ecosystem, which it believes to be one of the highest revenue-generating blockchains in the world, according to information provided by various blockchain data tracking sources, including Artemis Analytics and DefiLlama. At the same time, the company continues to execute on its planned completion of development and registration of its Optejet ophthalmic liquid delivery device. Hyperliquid is a layer one (L1) blockchain engineered for transparent high-frequency finance. Hyperion DeFi is also developing the proprietary Optejet User Filled Device (the Optejet UFD), which is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. As of December 31, 2025, the company had nine employees, all of which are full-time employees.

Written from the business description in Hyperion DeFi, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 813,455.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.8 · Net income -45.3
5M10M-20M-40M2016201720182019202020212022202320242025
Compound annual growth
−16.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −16.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−5571 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -5743.5% · Net -5570.6%
-200000%-400000%-600000%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -324.1%
-100%-200%-300%2016201720182019202020212022202320242025

Each USD of equity lost 324 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -30.3
-20M2016201720182019202020212022202320242025

Total assetsUSD 51.8M
EquityUSD 41.1M
CashUSD 6.4M
Current ratio2.68×

Equity funds 79% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.0·0.00.0····
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B·−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0·····0.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B·−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−9.40−59.81−53.15−0.83−0.49−0.94−1.47−1.82−2.19−1.56
Dividend / sh $··········
Payout %··········
ROE %−324.1·−207.8−148.6−71.4−146.2−147.9−157.1−126.7−117.4
Shares out B0.010.000.000.040.030.020.020.010.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 45 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 50 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image